版权说明 操作指南
首页 > 成果 > 详情

IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia

认领
导出
下载 Link by 万方学术期刊
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhang, Cai-ping;Tian, Ying;Zhang, Min;Tuo, Qin-hui;Chen, Jian-xiong;...
通讯作者:
Liao, DF
作者机构:
[Zhang, Cai-ping] Univ South China, Coll Med, 28 W Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
[Liao, Duan-fang; Chen, Jian-xiong; Tuo, Qin-hui] Hunan Univ Chinese Med, State Key Lab Chinese Med Powder & Med Innovat Hu, Div Stem Cell Regulat & Applicat, 300 Xueshi Rd, Changsha 410208, Hunan, Peoples R China.
[Tian, Ying; Zhang, Cai-ping; Zhang, Min] Univ South China, Dept Biochem & Mol Biol, 28 W Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
[Chen, Jian-xiong] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, University, MS 38677 USA.
[Liao, DF] Hunan Univ Chinese Med, 1 Xiangzui Rd, Changsha 410208, Hunan, Peoples R China.
通讯机构:
[Liao, DF ] H
Hunan Univ Chinese Med, 1 Xiangzui Rd, Changsha 410208, Hunan, Peoples R China.
语种:
英文
关键词:
atorvastatin;ESCRT protein;ezetimibe;hydroxymethylglutaryl coenzyme A reductase inhibitor;inducible degrader of low density lipoprotein receptor;kexin;liver X receptor;low density lipoprotein cholesterol;low density lipoprotein receptor;peptidase;proprotein convertase subtilisin kexin 9;rosuvastatin;serine proteinase;sterol regulatory element binding protein 2;ubiquitin protein ligase E3;ubiquitin specific peptidase 8;unclassified drug;antilipemic agent;low density lipoprotein receptor;MYLIP protein, human;ubiquitin protein ligase;Article;atherogenesis;cell surface;cholesterol blood level;coronary artery atherosclerosis;dyslipidemia;familial hypercholesterolemia;genetic association;Han Chinese;human;hyperlipidemia;lipid metabolism;multivesicular body;nonhuman;protein localization;protein targeting;single nucleotide polymorphism;biological model;drug effects;Dyslipidemias;metabolism;Dyslipidemias;Humans;Hypolipidemic Agents;Models, Biological;Receptors, LDL;Ubiquitin-Protein Ligases
期刊:
Medical Hypotheses
ISSN:
0306-9877
年:
2016
卷:
86
页码:
138-142
基金类别:
This work was supported by National Nature Science Fund of China (Nos. 81173047 , 31371161 ), Nature Science Fund of Hunan province (Nos. 15JJ6077 , 14JJ1024 , 14JJ3104 ), and the construct program of the Pharmaceutical Science key discipline in Hunan province .
机构署名:
本校为第一机构
院系归属:
化学化工学院
医学院
药学与生物科学学院
摘要:
Low-density lipoprotein cholesterol (LDL-C) is the hall marker for the atherosclerotic cardiovascular disease (ASCVD). It has been shown that over 70% of circulating LDL-C is metabolized through binding and activation of hepatic LDL receptor (LDLR). Genetic LDLR mutations cause hypercholesterolemia in the patients. Therefore, elevation of LDLR levels is beneficial for the treatment of dyslipidemia. LDLR expression is regulated by the SREBP2/PCSK9 pathways. Targeting SREBP2/PCSK9 pathways by statins and human monoclonal PCSK9 antibody has been shown to reduce the progression of ASVCD. Recent st...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com